to assess the effects of mitochondrial DNA (mtDNA) haplogroups on SARS-CoV-2 sensitivity

Grant number: INV-046722

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2022
  • Known Financial Commitments (USD)

    $2,324,617
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    United States of America
  • Lead Research Institution

    Children's Hospital of Philadelphia
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:43 minutes ago

View all publications at Europe PMC

Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes.

Mitochondrial antioxidants abate SARS-COV-2 pathology in mice.

SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19.